Iterative Health
Dana Feuchtbaum currently serves as the Chief Product Officer at Iterative Health, a position held since June 2023. Prior experience includes roles as SVP of Product at Nym and Senior Director of Product Management at Flatiron Health, among others. Dana has engaged in strategic consulting at The Avascent Group, providing management support to clients across civil and defense markets. Educational achievements include an MBA from Harvard Business School and a Bachelor of Arts in International Relations from Brown University, complemented by study at SOAS University of London.
This person is not in any teams
This person is not in any offices
Iterative Health
1 followers
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.
Employees
51-200